↑ parent cluster · ·
research dossier →

THE INTERNATIONAL GENOMICS CONSORTIUM

PHOENIX, AZ · EIN 861024333 · Form 990 · FY2021 · NTEE H30 · Medical Research · Medium ($1M-$10M) · www.intgen.org
revenue
$3.4M
expenses
$2.0M
net assets
$13.7M
employees
0
volunteers
2
program ratio
62%
mission · from form 990

WORK TO REVOLUTIONIZE THE TREATMENT AND PREVENTION OF CANCER AND COMPLEX DISEASES.

profile · synthesized from sources

The International Genomics Consortium (IGC) is a nonprofit medical research organization focused on accelerating the translation of genomic and molecular insights into medically useful information. It supports translational research by providing access to biospecimens, clinically annotated datasets, and genomic analyses for complex diseases, particularly cancer. IGC collaborates with academic centers, health systems, industry, and nonprofits to advance diagnosis, treatment, and patient outcomes.

irs program accomplishments · form 990 part iii · fy2021

what they reported doing

Program narrative the organization filed with the IRS. Ordered by program spending.

  1. #1 primary $3K
    VIOMICS - DIAGNOSTIC AND BIOMARKER RESEARCH WITH A FOCUS ON LUNG CANCER.
named programs · 4 · from sources

what they call their work

Biorepository and data access
Provides researchers worldwide with access to fully consented specimens and de-identified patient data and tumor profiles through collaborations with the National Cancer Institute and other partners.
Expression Project for Oncology (expO)
A publicly accessible biorepository linking cancer biospecimens, genomic data, and clinical outcomes to speed discovery.
Lung cancer early detection research
Research collaborating with investigators using data from the National Lung Screening Trial (NLST) to refine risk assessment and early detection strategies for lung cancer.
The Cancer Genome Atlas (TCGA) project
A project that delivers comprehensive genomic "blueprints" for many tumor types, enabling researchers worldwide to discover new diagnostic, prognostic, and therapeutic targets.
activities · 2 clusters

what they do

  • Genomic Research & Molecular Profiling 13 activities
    • Clinical validation of molecular profiling for cancer treatment
      Conducted clinical validation showing that approximately 25% of late-stage cancer patients treated based on Paradigm Cancer Diagnostic (PCDx) recommendations remained in remission, with an additional 25% experiencing improved progression-free survival, as published in July 2016.
    • Collaborative research in early cancer detection and biomarker discovery
      Conducts collaborative research in early detection and biomarker discovery, including lung cancer early detection using data from the National Lung Screening Trial to improve identification of suspicious nodules. Focuses on clinical genomics to enhance disease identification and enable personalized care.
    • Conduct collaborative research in early cancer detection and biomarker discovery
      Engages in collaborative research focused on early detection, biomarker discovery, and clinical genomics, including lung cancer nodule identification using National Lung Screening Trial data, to improve disease detection and enable personalized care.
    • Create and refine standards for biospecimen and genomic data practices
      Develops and refines best practices in consent, biospecimen collection, clinical annotation, molecular analysis, and data representation to support high-quality, ethical genomic research.
    • Development and refinement of biospecimen and genomic data standards
      Refines and promotes best practices in consent, biospecimen collection, clinical annotation, ethical handling, molecular analysis, and data representation to support high-quality, reproducible genomic research.
    • Enable global research access to consented biospecimens and de-identified data
      Provides open, unrestricted access to fully consented biospecimens, tumor profiles, and de-identified patient data for global research use, including transferring TCGA biospecimens to Nationwide Children’s Hospital for long-term stewardship.
    • Establish and maintain public cancer biorepositories with genomic and clinical data
      Created and curates one of the first large, publicly accessible biorepositories linking cancer biospecimens, genomic data, and clinical outcomes, including the Expression Project for Oncology (expO) launched in 2001, to accelerate oncology research and discovery.
    • Generate comprehensive genomic blueprints for tumor types
      Produces and contributed to molecular "blueprints" for multiple tumor types through participation in The Cancer Genome Atlas (TCGA), generating genomic and clinical datasets that inform global diagnostics, prognostics, and therapeutics.
    • Generation of comprehensive genomic blueprints for tumor types
      Produces and contributed to molecular "blueprints" for multiple tumor types through participation in The Cancer Genome Atlas (TCGA), serving as a founding Biospecimen Core Resource and Tissue Source Site since 2006. Generated genomic and clinical datasets that are freely available and used globally to inform diagnostics, prognostics, and therapeutics.
    • Operation of a public cancer biorepository and genomic data resource
      Established and maintains one of the first large, publicly accessible biorepositories linking cancer biospecimens, genomic data, and clinical outcomes, including the Expression Project for Oncology (expO) launched in 2001. Provides global research access to fully consented biospecimens and de-identified patient data and tumor profiles to accelerate oncology discoveries.
    • Spearhead joint ventures for clinical molecular profiling
      Spearheaded the development of Paradigm, a joint venture with the University of Michigan Health System, to deliver molecular profiling services to oncology patients, with clinical validation showing improved remission and progression-free survival in late-stage cancer patients.
    • Spin out genomic technologies into biotechnology companies
      Developed and spun out technologies now utilized by leading biotechnology and diagnostics companies, contributing to commercial innovation in genomics and personalized medicine.
    • Support the formation and development of genomics-focused organizations
      Played a foundational role in launching and supporting multiple genomics and diagnostics organizations, including TGen, Molecular Profiling Institute (now Caris Life Sciences), Paradigm Diagnostics, and Viomics, to advance molecular profiling and early cancer detection.
  • Uncategorized 1 activity
    • Support and spinout of biotechnology and molecular diagnostics ventures
      Incubated and supported the formation of multiple biotechnology and molecular diagnostics companies, including the Translational Genomics Research Institute (TGen), Molecular Profiling Institute (now Caris Life Sciences), Paradigm Diagnostics, and Viomics. Co-founded Paradigm, a joint venture with the University of Michigan Health System, to deliver molecular profiling to oncology patients.
financials · form 990 · fy2021

the money

revenue
Total revenue$3.35M
Contributions & grants$1.00M30%
Program service revenue$1380%
Investment income$940K28%
Other revenue$1.41M
expenses
Total expenses$2.00M
Program expenses62%
Admin / overhead38%
Fundraising0%
Salaries & benefits$440K
Grants paid out$0
Largest expense lineFacilities
balance sheet
Total assets$13.87M
Cash$1.90M
Investments$9.93M
Liabilities$139K
Net assets$13.73M
Liquid reserves70.8 mo
2 years on record · 2020–2021 · YoY revenue -77.5%
leadership · form 990 part vii · fy2021

who runs it

paid leadership · 5
NameTitleHours/wkCompensation
DAVID MALLERY PRESIDENT & CEO 20 $240K
SCOTT MORRIS CHIEF SCIENTIFIC OFFICER 20 $120K
TROY SHELTON BOARD MEMBER, VP OF OPERATIONS 20 $48K
VANESA ROMERO CFO 16 $36K
ROBERT ARMKNECHT JR BOARD MEMBER 1 $20K
board members · 2
  • ERIN CURLEY — BOARD MEMBER
  • LEE ANN BOHN — BOARD MEMBER
relationships · 18

who they work with

  • American Cancer Society Partner — Cites American Cancer Society reports to support context on cancer prevention, early detection, and mortality trends.
  • Caris Life Sciences Partner — The Molecular Profiling Institute is now part of Caris Life Sciences.
  • Cirrus Bio Partner — The co-founders of IGC also founded Cirrus Bio.
  • City of Hope Partner — TGen is now an affiliate of City of Hope.
  • Exact Sciences Partner — Paradigm and Viomics were acquired by Exact Sciences.
  • Maricopa County Funder — Provided primary and initial support.
  • Maverix Medical Partner — Cirrus Bio is now part of Maverix Medical.
  • Molecular Profiling Institute Partner — Helped launch the institute in collaboration with TGen.
  • National Cancer Institute Partner — Research collaborator on lung cancer early detection and The Cancer Genome Atlas (TCGA)
  • National Human Genome Research Institute Partner — Co-founding partner in The Cancer Genome Atlas (TCGA)
  • National Institute of Health Partner — Collaborated with researchers to create a large publicly available biorepository.
  • Nationwide Children’s Hospital Partner — Steward of TCGA biospecimens following project completion
  • Paradigm Diagnostics Partner — Supported its formation in collaboration with the University of Michigan Health system.
  • Precision for Medicine Partner — Holds residual specimens from the Expression Project for Oncology (expO)
  • Translational Genomics Research Institute (TGen) Partner — Played a foundational role in its formation.
  • University of Michigan Health System Partner — Collaborated on the formation of Paradigm Diagnostics and Paradigm, a joint venture.
  • Viomics Partner — Supported its development.
  • Vivia Oncology Partner — A biotech company focused on high-throughput drug development.